Global dialogue on dementia and an ageing society
Wednesday 30 June 2021
A global dialogue on dementia and an ageing society took place on 30 June 2021 and was co-chaired by Professor Shekhar Saxena, Professor of the Practice of Global Mental Health at Harvard and a member of the World Dementia Council, and Sarah Lock, Senior Vice President for Policy at AARP.
Global dialogue on health systems readiness and dementia
Wednesday 7 July 2021
A global dialogue on dementia and health systems readiness on 7 July 2021 will gather international leaders to discuss this area of focus as part of the dementia landscape project. This dialogue will be led by Dr Margaret Hamburg, former Commissioner of the US Food and Drug Administration and member of the World Dementia Council, and Professor Howard Bergman, Professor of Family Medicine, Medicine (Geriatrics), and Oncology at McGill University.
A data sharing global dialogue was co-chaired by Dr Lara Mangravite, president of Sage Bionetworks, and Dr Tetsu Maruyama, executive director of the Alzheimer's Disease Data Initiative (ADDI) and a member of the World Dementia Council.
Wednesday 9 June 2021
Dr Lara Mangravite
Lara Mangravite, PhD, is President of Sage Bionetworks. This organization is focused on the development and implementation of practices for large-scale collaborative biomedical research. Our work is centered on new approaches to scientific process that use open systems to enable community-based research regarding complex biomedical problems. Previously, Dr. Mangravite served as Director of the Systems Biology research group at Sage Bionetworks where she focused on the application of collaborative approaches to advance understanding of disease biology and treatment outcomes at a systems level with the overriding goal of improving clinical care. Dr. Mangravite obtained a BS in Physics from the Pennsylvania State University and a PhD in Pharmaceutical Chemistry from the University of California, San Francisco. She completed a postdoctoral fellowship in cardiovascular pharmacogenomics at the Children’s Hospital Oakland Research Institute.
Dr Tetsu Maruyama
Tetsu Maruyama is the Executive Director of the ADDI, where he has the pleasure of working with an exceptional team to enable data relevant to Alzheimer’s and related dementias to reach their full potential. Prior to joining ADDI, Tetsu was the Chief Scientific Officer at the Dementia Discovery Fund, a unique venture capital fund focusing a total investment of $350 million on creating new treatment paradigms for dementia. Before that he was head of Drug Discovery for Takeda Pharmaceuticals in Japan, after leading the GlaxoSmithKline Centre for Cognitive and Neurodegenerative Disorders in Singapore. He began his industry career at Merck Sharp and Dohme’s Neuroscience Research Center in the UK, after 15 years as an academic neuroscientist at Cardiff University and the University of Minnesota.
Dr Angela Bradshaw
Dr. Angela Bradshaw is a Project Officer at Alzheimer Europe, an umbrella organisation of national Alzheimer’s Associations with 39 members across 35 European countries. Alzheimer Europe aims to change perceptions, practice and policy, promoting a rights-based approach to dementia and working to make dementia a European priority. Angela collaborates on several EU-funded projects involving AI and health data, co-authoring the recent policy report “Data sharing in dementia research – the EU landscape”. She obtained her PhD in vascular biology at the University of Cambridge, and worked as a lecturer at the University of Glasgow prior to joining Alzheimer Europe.
Professor Andrew Morris
Professor Andrew Morris became the inaugural Director of Health Data Research UK in August 2017. He is seconded from his position as Professor of Medicine, and Vice Principal of Data Science at the University of Edinburgh, having taken up position in August 2014. Prior to this Andrew was Dean of Medicine at the University of Dundee. Andrew was Chief Scientist at the Scottish Government Health Directorate (2012-2017) and has served and chaired numerous national and international grant committees and Governmental bodies. His research interests span informatics and chronic diseases.
Dr Suzana Petanceska
Dr Petanceska joined the National Institute on Aging in 2005, as a program director in the Division of Neuroscience. During her tenure at the NIA she has been overseeing and developing a number of research portfolios and programs in basic and translational research for Alzheimer’s disease. She has been instrumental for the development of NIA’s AD Translational Research program, the Epigenomics of AD portfolio and the Accelerated Medicines Partnership for AD (AMP AD) – Target Discovery and Preclinical Validation Project. Since 2012 she has been leading a number of NIA’s strategic planning activities related to achieving the research goal of the National Plan to Address Alzheimer’s: to prevent and treat AD by 2025.
Other dialogues in the series
To inform the dementia landscape report, the Council has hosted global dialogues for international dementia leaders focusing on key themes of research, care and prevention that were identified at the London dementia summit in 2013, as well as on additional key themes and new policy priorities that we have agreed to highlight in the report, including data sharing and dementia registries, and the impact of dementia on low- and middle-income countries. See more below.